News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Drug interactions and pharmacokinetics
Frequent drug-drug interactions in older people with HIV in France

Drug-drug interactions are common in people over the age of 65 living with HIV and this substantially increases healthcare costs in France. Published in Open Forum Infectious Diseases,

Published
19 June 2019
By
Alain Volny-Anne
Bone and joint problems
Aging HIV population face complicated rheumatologic care

As the national population of patients who are HIV-positive continues to age, rheumatologists will be increasingly called on to manage routine care for crystal disease, osteoarthritis, soft tissue rheumatism and other conditions, according to Leonard Calabrese, DO, of the Cleveland Clinic.

Published
22 May 2019
From
Healio
Chemsex and recreational drug use
One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

One in 3 people in a 286-person French HIV group took illicit drugs that sometimes posed a risk of severe interactions with antiretrovirals. Many potential interactions involved the boosting agents ritonavir or cobicistat.

Published
17 May 2019
From
NATAP
PrEP science
Some people may have genes that hamper a drug's HIV protection

Some people’s genes may stop an antiretroviral drug from protecting them against HIV, a genetics study suggests.

Published
13 May 2019
From
Science News
Drug interactions and pharmacokinetics
Do Feminizing Hormones Impact Efficacy of PrEP Drugs?

A team of investigators is examining why some transgender women taking hormones may need higher levels of PrEP medication.

Published
29 April 2019
From
Contagion Live
Transgender people
The largest study involving transgender people is providing long-sought insights about their health

The research examines once taboo questions about the impacts of gender transition. The European Network for the Investigation of Gender Incongruence (ENIGI) is the largest scientific study of transgender people in the world, now with 2600 participants, and is unique because it is prospective, studying the impact of hormone and other therapies on their health over the long term.

Published
25 April 2019
From
Nature
Prevention of mother-to-child transmission
Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

Published
17 April 2019
From
Medicines and Healthcare products Regulatory Agency
Contraception
Efavirenz and rifampicin together reduce levels of injectable contraception

Women with HIV receiving depot medroxyprogesterone acetate (DMPA), with efavirenz (EFV)-based ART and rifampicin (RIF)-based TB treatment, had lower MPA plasma levels compared with women not receiving the two drugs.

Published
29 March 2019
From
HIV i-Base
Contraception
Double-dose levonorgestrel implant does not overcome interaction with efavirenz

Using two levonorgestrel (LNG) implants does not fully overcome the drug-drug interaction with efavirenz (EFV) – according to findings from a pharmacokinetic (PK) evaluation of double-dose LNG in Ugandan women receiving EFV-based ART.

Published
29 March 2019
From
HIV i-Base
Drug-resistant TB
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
← First12345...24Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.